MC2096A1 - SUBSTITUTED PYRROLES - Google Patents

SUBSTITUTED PYRROLES

Info

Publication number
MC2096A1
MC2096A1 MC902110A MC2110A MC2096A1 MC 2096 A1 MC2096 A1 MC 2096A1 MC 902110 A MC902110 A MC 902110A MC 2110 A MC2110 A MC 2110A MC 2096 A1 MC2096 A1 MC 2096A1
Authority
MC
Monaco
Prior art keywords
substituted pyrroles
active substances
derivatives
substances
furandione
Prior art date
Application number
MC902110A
Other languages
French (fr)
Inventor
David Davis Peter
Huw Hill Christopher
Lawton Geoffrey
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898904161A external-priority patent/GB8904161D0/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MC2096A1 publication Critical patent/MC2096A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Pyridine Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

The pyrrole derivatives of the formula <IMAGE> in which R<1> to R<8>, R, X, Y and m have the meaning given in the description, are therapeutically active substances, in particular for use as substances having antiinflammatory, immunological, oncological, bronchopulmonary and cardiovascular activity or as active substances in the treatment of asthma or AIDS. They are prepared from corresponding furandione derivatives in which X and Y stand for =N-R or O.
MC902110A 1989-02-23 1990-02-16 SUBSTITUTED PYRROLES MC2096A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898904161A GB8904161D0 (en) 1989-02-23 1989-02-23 Substituted pyrroles
GB898928210A GB8928210D0 (en) 1989-02-23 1989-12-13 Substituted pyrroles

Publications (1)

Publication Number Publication Date
MC2096A1 true MC2096A1 (en) 1991-02-15

Family

ID=26295005

Family Applications (1)

Application Number Title Priority Date Filing Date
MC902110A MC2096A1 (en) 1989-02-23 1990-02-16 SUBSTITUTED PYRROLES

Country Status (20)

Country Link
EP (1) EP0384349B1 (en)
JP (1) JPH06102661B2 (en)
AT (1) ATE104972T1 (en)
AU (1) AU633051B2 (en)
CA (1) CA2010636C (en)
CZ (1) CZ284587B6 (en)
DE (1) DE59005491D1 (en)
DK (1) DK0384349T3 (en)
DZ (1) DZ1399A1 (en)
ES (1) ES2052995T3 (en)
FI (1) FI93447C (en)
HU (1) HU206351B (en)
IE (1) IE64184B1 (en)
IL (1) IL93433A (en)
MC (1) MC2096A1 (en)
NO (1) NO174891C (en)
NZ (1) NZ232589A (en)
PT (1) PT93246B (en)
RU (2) RU2014332C1 (en)
SK (1) SK278711B6 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
DE4128015A1 (en) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-ANELLIZED 2- (PIPERAZINOALKYL) INDOL DERIVATIVES AND METHODS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING SUCH COMPOUNDS
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
JPH07504673A (en) * 1992-03-20 1995-05-25 ザ・ウエルカム・ファウンデーション・リミテッド Indole derivatives with antiviral activity
US5721230A (en) * 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5405864A (en) * 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
FI945705L (en) * 1993-12-07 1996-06-03 Lilly Co Eli Improved synthesis of bisindolylmaleimides
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
JP3581731B2 (en) * 1993-12-07 2004-10-27 イーライ・リリー・アンド・カンパニー Protein kinase C inhibitor
US5843935A (en) * 1993-12-07 1998-12-01 Eli Lilly And Company Protein kinase C inhibitors
US5541347A (en) * 1993-12-07 1996-07-30 Eli Lilly And Company Synthesis of bisindolylmaleimides
DE69434294T2 (en) * 1993-12-23 2005-12-29 Eli Lilly And Co., Indianapolis Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
ATE172463T1 (en) * 1994-08-04 1998-11-15 Hoffmann La Roche PYRROLOCARBAZOLE
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
CN1145623C (en) * 1994-12-13 2004-04-14 霍夫曼-拉罗奇有限公司 Imidazole derivatives
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
CA2268399C (en) * 1996-10-31 2008-08-19 Harbor Branch Oceanographic Institution, Inc. Anti-neurogenic inflammatory compounds and compositions and methods of use thereof
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
EP1224932A4 (en) * 1999-08-20 2002-10-16 Sagami Chem Res DRUGS INHIBITING CELL DEATH
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
CA2417277A1 (en) 2000-07-27 2002-02-07 F. Hoffmann-La Roche Ag 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3.beta.
EP1362047B1 (en) 2000-12-08 2006-05-17 Ortho-McNeil Pharmaceutical, Inc. Indazolyl-substituted pyrroline compounds as kinase inhibitors
TW201041580A (en) 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
ATE302771T1 (en) * 2001-12-27 2005-09-15 Theravance Inc INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS
TWI324064B (en) * 2002-04-03 2010-05-01 Novartis Ag Indolylmaleimide derivatives
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
AU2004262927B2 (en) 2003-08-08 2008-05-22 Novartis Ag Combinations comprising staurosporines
EP1709030B1 (en) * 2004-01-19 2008-04-02 Novartis AG Indolylmaleimide derivatives
EP1814882A1 (en) * 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
JP5289769B2 (en) 2004-12-08 2013-09-11 ヨハネス、グーテンベルク−ウニフェルジテート、マインツ 3- (Indolyl) -4-arylmaleimide derivatives and their use as angiogenesis inhibitors
ES2354267T3 (en) 2005-02-09 2011-03-11 Arqule, Inc. MALEIMIDA DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER.
DE602006019732D1 (en) 2005-07-11 2011-03-03 Novartis Ag INDOLYLMALEIMIDDERIVATE
ES2443022T3 (en) * 2005-08-12 2014-02-17 Merck Frosst Canada Inc. Indole derivatives as CRTH2 receptor antagonists
EP1980561B1 (en) 2007-03-30 2013-10-09 Nerviano Medical Sciences S.R.L. Substituted 1h-pyrazolo[3,4-b] pyridine derivatives active as kinase inhibitors
WO2009002806A1 (en) * 2007-06-22 2008-12-31 Arqule, Inc. Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
CN101801937A (en) 2007-06-22 2010-08-11 艾科尔公司 Quinazolinone compounds and methods of use thereof
US8513292B2 (en) 2007-06-22 2013-08-20 Arqule, Inc. Compositions and methods for the treatment of cancer
CA2737483A1 (en) * 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists
EP2343291A1 (en) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2011082266A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted heterocyclic compounds
EP2474541A1 (en) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
MX2015014907A (en) * 2013-04-23 2016-03-07 Esteve Labor Dr PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS.
EP3741375A1 (en) 2014-07-17 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
EP3187495A1 (en) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
US5049563A (en) * 1988-07-07 1991-09-17 Duphar International Research B.V. Annelated indoleketones with an imidazolylalkyl substituent

Also Published As

Publication number Publication date
FI93447B (en) 1994-12-30
FI93447C (en) 1995-04-10
FI900863A0 (en) 1990-02-21
EP0384349B1 (en) 1994-04-27
AU5003390A (en) 1990-08-30
DE59005491D1 (en) 1994-06-01
IL93433A (en) 1996-11-14
ATE104972T1 (en) 1994-05-15
RU2142460C1 (en) 1999-12-10
JPH06102661B2 (en) 1994-12-14
NO174891C (en) 1994-07-27
NO900855D0 (en) 1990-02-22
NO900855L (en) 1990-08-24
CA2010636C (en) 1999-12-14
ES2052995T3 (en) 1994-07-16
CZ85590A3 (en) 1998-10-14
NZ232589A (en) 1992-09-25
HU206351B (en) 1992-10-28
HU900846D0 (en) 1990-04-28
IL93433A0 (en) 1990-11-29
JPH02264776A (en) 1990-10-29
IE64184B1 (en) 1995-07-12
EP0384349A1 (en) 1990-08-29
RU2014332C1 (en) 1994-06-15
SK85590A3 (en) 1998-01-14
NO174891B (en) 1994-04-18
IE900647L (en) 1990-08-23
PT93246A (en) 1990-08-31
CZ284587B6 (en) 1999-01-13
DZ1399A1 (en) 2004-09-13
SK278711B6 (en) 1998-01-14
CA2010636A1 (en) 1990-08-23
AU633051B2 (en) 1993-01-21
HUT53369A (en) 1990-10-28
PT93246B (en) 1996-01-31
DK0384349T3 (en) 1994-09-05

Similar Documents

Publication Publication Date Title
MC2096A1 (en) SUBSTITUTED PYRROLES
FI96204C (en) Process for the preparation of therapeutically useful heterocyclic compounds
RU93033479A (en) METHOD FOR OBTAINING SUBSTITUTED PYRROLES, METHOD FOR OBTAINING PHARMACEUTICAL PREPARATIONS
CA2107105A1 (en) Heterocyclic-cyclic amine derivatives
DE3880047D1 (en) COMPOSITION OF AN ADDITION.
NO180083C (en) Preparation of substituted piperidines
NO971625L (en) Novel peptides with immunomodulatory effects
DE69813565D1 (en) SUBSTITUTED 3,3-DIAMINO-2-PROPENNITRILE, THEIR PRODUCTION AND USE
NO905288D0 (en) PROCEDURE FOR AA INCREASES THE SPECIFIC WEIGHT OF RODSLAM SOLID.
FI881609A0 (en) DIHYDROPYRIDINAMIDER, FOERFARANDE FOER DERAS FRAMSTAELLNING OCH DERAS ANVAENDNING I LAEKEMEDEL.
ATE92469T1 (en) NEW ALPHA-AMINOCARBONIC ACID DERIVATIVES, THEIR PREPARATION AND USE.
DE69231883D1 (en) 4- (1,1-dialkoxycarbonyl-alkyl) azetidin-2-one derivatives for the preparation of 4- (1-carboxy-alkyl) azetidin-2-one derivatives
FI942468A0 (en) Chemical compounds, their preparation and use
DE3851979D1 (en) Substituted vinyl cephalosporins, processes for their preparation and their use as medicines.
ATE100102T1 (en) SUBSTITUTED DERIVATIVES OF 20,21DINOREBUNAMENINE, PROCESSES FOR THE MANUFACTURE AND INTERMEDIATE PRODUCTS SO MANUFACTURED, THEIR USE AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2058196T3 (en) DERIVATIVES OF AZACROMANO.
FI906162A0 (en) PROCEDURE FOR FRAMSTATION OF AV 3- (N-METHYL-N-ALKYL) -AMINO-2-METOXIMETHYLENPROPAN-1-OLDERIVAT.
DK0418990T3 (en) 13-bromo- and 13,14-dibromo-ergolines, their preparation and use in pharmaceuticals
DE59206026D1 (en) Derivatives of 2,2-dihalobenzo (1,3) dioxoles substituted in the 4-position, process for their preparation and their use
IE840831L (en) 1,4-dihydropyridine derivatives
NO883381D0 (en) PROCEDURE FOR THE PREPARATION OF N - (((4-HYDROSY-PYRROLIDIN-2-ON-1-YL) -ACETYL) -GYLCINAMIDE.
NO931072D0 (en) PROCEDURE FOR THE PREPARATION OF POLYHYDRAPHYETIC ACID AMIDES IN THE PRESENT OF SOLVENTS

Legal Events

Date Code Title Description
YP Annual fee paid
YP Annual fee paid